Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Cytisinicline in Renal Impairment
NCT05631938Phase 1Completed
- Sponsor
- Achieve Life Sciences
- Start
- Jan 2023
- Primary completion
- Sep 2023
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
Phase 1, open-label trial of cytisinicline in nicotine dependence (5 arms), sponsored by Achieve Life Sciences. Primary endpoints: Maximum Observed Plasma Concentration at 48 hours, Time of Occurrence of Cmax and 10 more. Started Jan 2023; status: completed.
02
Drugs
cytisinicline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT05631938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05631938.